Melphalan Tillomed (Melphalan)

Melphalan works by alkylating DNA guanine bases, creating cross‑links that block DNA replication and transcription. This damage prevents cancer cells from dividing and triggers programmed cell death, reducing tumor growth.

The dosage of melphalan is individualized and determined by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal function, and treatment protocol. No standard dose is provided here.

Melphalan is classified as contraindicated in pregnancy because it can cause fetal harm. It is also not recommended during breastfeeding, as it may be excreted in milk and affect the infant. Consultation with a specialist is essential before any exposure.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Melphalan shares the DNA‑cross‑linking mechanism of other alkylators such as cyclophosphamide, but it is often preferred for certain hematologic cancers like multiple myeloma due to its potency and pharmacokinetic profile. Choice of agent depends on cancer type, prior therapy, and tolerability.

Melphalan Tillomed must be stored at 2‑8 °C in a refrigerator, protected from light, and should not be frozen or shaken. The product should remain in its original packaging until use to maintain stability.

Melphalan is given as an intravenous injection or infusion by a qualified healthcare professional. The preparation is diluted according to the prescribing information and administered over a controlled period to ensure safety and efficacy.

The most serious risks include severe myelosuppression leading to infection, anemia, or bleeding; secondary acute leukemia; and pulmonary toxicity such as interstitial pneumonitis. Patients should be monitored closely for these complications throughout treatment.

Melphalan should not be used in patients with known hypersensitivity to the drug, active uncontrolled infections, severe bone‑marrow failure, or in pregnant women unless absolutely necessary. Clinicians must evaluate each patient’s medical history before initiating therapy.